NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 1 நாளுக்கு முன்இன்று 91 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Godrej Agrovet Q2 FY27: Consolidated Revenue Up 17% to ₹2,995 Cr, PAT Rises 22% to ₹103 Cr
Godrej Agrovet submitted its Q2 FY27 earnings conference call transcript, reporting a 17% YoY growth in consolidated revenue to ₹2,995 crore. Profit after tax (PAT) rose 22% YoY to ₹103 crore, while EBITDA stood stable at ₹222 crore with an EBITDA margin of 7.4%. Performance was driven by animal nutrition (revenue up 14%, profit up 32%) and oil palm (revenue up 28%), which offset headwinds in crop care and Astec LifeSciences caused by adverse weather and weak enterprise demand. For H1 FY27, consolidated revenue grew 13% to ₹5,847 crore with a PAT of ₹231 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுFiling of the official transcript of the Q2 FY27 earnings conference call conducted on November 6, 2026.
ஏன் இது முக்கியம்Provides detailed management commentary on operational performance, segment resilience against El Niño headwinds, margin trajectories, and capacity additions in the oil palm business.
Q2 FY27 Consolidated Revenue: ₹2,995 கோடிQ2 FY27 Consolidated PAT: ₹103 கோடிQ2 FY27 EBITDA Margin: 7.4%H1 FY27 Area Added (Oil Palm): 13,000 hectaresNet Working Capital Days: 21 days (vs 32 days last year)
📅 குறுகிய காலம்Near-term market sentiment should remain supported by double-digit top-line and bottom-line growth despite weather-induced headwinds in the crop care division.
📈 நீண்ட காலம்Expansion into higher-margin segments like palm oil derivatives, premium B2C foods, and structural working capital reduction support long-term ROCE enhancement.
⚠ அபாய எச்சரிக்கைகள்
Adverse climate conditions (El Niño, rainfall deficits) reducing oil extraction ratios and hitting crop care demand
Input cost inflation in milk, feed, packaging, and logistics
Persistent demand softness in Astec LifeSciences' enterprise segment
👀 கவனிக்க வேண்டியவை
Track the commissioning and contribution of the upcoming refinery in the Khammam integrated oil palm complex, alongside margin recovery in Astec LifeSciences and crop care across H2 FY27.
Godrej Agrovet Q2 FY27 Investor Presentation: Revenue Up 17% to ₹2,995 Cr, PAT Up 22% to ₹103 Cr
Godrej Agrovet reported a 17% YoY increase in consolidated revenue to ₹2,995 crore for Q2 FY27, up from ₹2,564 crore in Q2 FY26. Consolidated EBITDA remained flat at ₹222 crore, with EBITDA margin contracting by 120 bps to 7.4% due to input cost inflation and El Niño-led climate disruptions. Profit after tax (before non-controlling interest) rose 22% YoY to ₹103 crore, driven by Animal Nutrition (EBIT up 32%) and Oil Palm revenue growth (+28%). For H1 FY27, revenue reached ₹5,847 crore (+13% YoY) while reported EBITDA fell 5% to ₹476 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுGodrej Agrovet published its detailed Q2 & H1 FY27 investor presentation following the board's approval of unaudited financial results on November 6, 2026.
ஏன் இது முக்கியம்Demonstrates top-line resilience driven by Oil Palm and Animal Nutrition, but highlights persistent margin compression across dairy, crop care, and Astec Lifesciences due to input cost pressures and monsoon anomalies.
📅 குறுகிய காலம்Market focus will likely center on margin headwinds caused by raw material inflation and weak performance in the agrochemicals subsidiary (Astec Lifesciences), balancing out steady volume growth in feeds.
📈 நீண்ட காலம்Strategic focus on premium cattle feeds, specialty fats from palm oil, and increasing value-added dairy/food salience supports multi-year margin expansion, though cyclical climate risks remain a factor.
⚠ அபாய எச்சரிக்கைகள்
Input cost inflation in milk, packaging, and feed inputs impacting EBITDA margins.
Subdued demand and severe margin contraction (-1,900 bps) in Astec Lifesciences.
El Niño impact and low reservoir levels posing downside risks to rabi crop acreage.
👀 கவனிக்க வேண்டியவை
Track the impact of monsoon shortfalls and low reservoir levels on upcoming rabi crop demand, alongside margin stabilization in Astec Lifesciences and Creamline Dairy.
Godrej Agrovet Q2 PAT Attributable Rises 24.4% YoY to Rs 115.21 Cr; Revenue Up 16.7%
Godrej Agrovet reported consolidated revenue from operations of Rs 2,994.98 crore for Q2 ended September 30, 2026, marking a 16.65% increase year-on-year from Rs 2,567.42 crore. Profit before exceptional items and tax stood at Rs 143.24 crore compared to Rs 135.06 crore in Q2 FY25. Consolidated net profit attributable to owners rose 24.43% YoY to Rs 115.21 crore from Rs 92.59 crore, with diluted EPS expanding to Rs 5.99 from Rs 4.81. On a sequential basis, revenue grew 4.9% from Rs 2,855.22 crore in Q1, while total profit for the period softened to Rs 102.75 crore from Rs 128.31 crore.
உச்சம் நம்பிக்கை
என்ன மாறியதுGodrej Agrovet approved and published unaudited Q2 and H1 FY27 financial results showing healthy double-digit YoY top-line and net profit expansion.
ஏன் இது முக்கியம்Shows operational resilience against commodity price swings across agricultural feeds and palm oil segments, sustaining bottom-line growth.
Consolidated Q2 Revenue: Rs 2,994.98 கோடிConsolidated Q2 Net Profit (Total): Rs 102.75 கோடிConsolidated Q2 PAT Attributable: Rs 115.21 கோடிDiluted EPS (Q2): Rs 5.99Consolidated H1 Revenue: Rs 5,850.20 கோடி
📅 குறுகிய காலம்Market sentiment should react positively to the 24.4% YoY jump in attributable profit, although sequentially PAT moderated from Rs 128.31 cr in Q1.
📈 நீண்ட காலம்Earnings trajectory remains tied to diversification into higher-margin palm oil and CDMO segments while managing raw material volatility in feed operations.
⚠ அபாய எச்சரிக்கைகள்
Subsidiary losses (Astec LifeSciences / NCI drag) reduced total consolidated profit by Rs 12.46 cr
Susceptibility to raw material price inflation across feed and oil segments
👀 கவனிக்க வேண்டியவை
Track segment-wise performance in the investor presentation to monitor margin trends across animal feed, palm oil, and Astec LifeSciences CDMO business.
Godrej Agrovet Crop Care CEO Rajavelu N.K Resigns, Effective November 24, 2026
Godrej Agrovet announced the resignation of Rajavelu N.K, Chief Executive Officer of its Crop Care business, on September 21, 2026. The executive is stepping down to pursue an external opportunity, with his last working day set for November 24, 2026. A handover process will take place over the transitional weeks across this core business segment. The Crop Care vertical forms a strategic part of Godrej Agrovet's high-margin growth focus within its Rs 10,474 Cr TTM revenue base.
உச்சம் நம்பிக்கை
என்ன மாறியதுRajavelu N.K has resigned as the CEO of the Crop Care business, serving notice until November 24, 2026.
ஏன் இது முக்கியம்The Crop Care business is an important margin driver for Godrej Agrovet, making leadership continuity critical during competitive industry conditions.
Resignation Date: 21 செப்டம்பர் 2026Last Working Day: 24th நவம்பர் 2026Company TTM Revenue Context: Rs 10474 கோடி
📅 குறுகிய காலம்Neutral market reaction expected as the executive is serving a two-month transition period ending late November 2026.
📈 நீண்ட காலம்Limited operational disruption expected assuming an orderly handover and the appointment of an experienced replacement.
⚠ அபாய எச்சரிக்கைகள்
Potential transitional disruption in the Crop Care vertical leadership
👀 கவனிக்க வேண்டியவை
Track the announcement of the successor for the Crop Care division and watch for any execution disruptions in the agrochemicals segment during Q3 FY27 results.
10% Revenue Growth in Q1 FY27; Animal Nutrition and Oil Palm Drive Performance
Godrej Agrovet reported a 10% YoY increase in consolidated sales to ₹2,852 Cr for Q1 FY27, despite macro headwinds like a delayed monsoon. Growth was primarily driven by the Animal Nutrition segment (+12.6% revenue) and Oil Palm (+28.9% revenue), while the standalone Crop Care business saw a 16.2% decline. Notably, Astec LifeSciences reached EBITDA breakeven compared to an ₹11 Cr loss in the previous year, and the Dairy segment increased its value-added product salience to 49%. Management highlighted significant improvements in average net working capital and continued focus on portfolio diversification.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has successfully turned around Astec LifeSciences to EBITDA breakeven and significantly increased the contribution of high-margin value-added products in the Dairy business.
ஏன் இது முக்கியம்The results demonstrate the company's ability to maintain growth through diversification, reducing its historical dependence on seasonal crop protection and volatile animal feed segments.
📅 குறுகிய காலம்The stock may see positive sentiment as strong performance in core segments like Animal Nutrition and Oil Palm offsets the temporary weakness in Crop Care.
📈 நீண்ட காலம்Structural improvements in working capital and a shift toward value-added products and CDMO services are likely to enhance long-term ROCE and margin stability.
👀 கவனிக்க வேண்டியவை
Investors should monitor the scale-up of new product launches in Crop Care (Ashitaka, Takai) to see if they can offset the volatility in the cotton herbicide segment. Additionally, track the impact of elevated milk procurement prices on Dairy margins in the upcoming quarters.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Q1 FY27: Godrej Agrovet Revenue grows 10% to Rs 2,852 Cr; PAT drops 14% on Crop Care weakness
Godrej Agrovet reported a 10% YoY revenue growth in Q1 FY27, reaching Rs 2,852 Cr, led by strong performance in Animal Nutrition and Oil Palm. However, consolidated PAT declined 14% to Rs 128 Cr as EBITDA margins contracted to 8.9% from 10.8% in the previous year. The decline was primarily driven by the Crop Care segment, where revenue fell 17% due to the driest June in over a decade. The company announced a strategic 'structural reset,' including the exit from Live Bird Trading and a review of the Shrimp Feed business to focus on higher-margin segments.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has initiated a structural portfolio reset, moving away from a commodity-led mindset to a customer-facing approach, which includes closing the Live Bird Trading business and evaluating the closure of select underperforming plants.
ஏன் இது முக்கியம்This strategic shift aims to improve overall ROCE and margins by allocating capital to high-growth areas like CDMO (Astec) and value-added dairy, reducing the impact of volatile commodity cycles.
Q1 FY27 Sales: Rs 2,852 கோடிPAT (Reported) Growth: -14% YoYCattle Feed Volume Growth: 15%Annual Capex Guidance: Rs 300 - 350 CrCapex vs Net Worth: ~12.1%CPO Realisations: Rs 1,34,783 per MT
📅 குறுகிய காலம்The stock may face near-term pressure due to the 14% PAT decline and margin contraction, though strong volume growth in the feed business provides some fundamental support.
📈 நீண்ட காலம்The structural reset and focus on specialized segments like CDMO and value-added foods could lead to a long-term re-rating if the company successfully improves its ROCE and reduces commodity-linked volatility.
⚠ அபாய எச்சரிக்கைகள்
Weather dependency (monsoon impact on Crop Care and Palm Oil)
Commodity price volatility in raw materials for animal feed
Execution risk in exiting and restructuring business segments
👀 கவனிக்க வேண்டியவை
Watch for the recovery in Crop Care margins in Q2 as monsoon coverage improves and monitor the execution of the planned exit from the low-margin Live Bird Trading business.
Q1 FY27 Results: Revenue up 9.5% to ₹2,852 Cr; PBT declines 8.5% on cost headwinds
Godrej Agrovet reported a 9.5% YoY increase in consolidated sales to ₹2,852 crore for Q1 FY27, driven by strong volume growth in Animal Nutrition and Dairy segments. However, Profit Before Tax (excluding non-recurring items) fell by 8.5% to ₹172 crore due to delayed monsoons impacting Crop Care and milk inflation affecting Dairy margins. Animal Nutrition was a standout performer with a 36% YoY jump in segment results, while Astec LifeSciences continued its recovery toward EBITDA break-even. The Dairy segment saw a significant shift toward value-added products, now comprising 49% of sales compared to 42% last year.
உச்சம் நம்பிக்கை
என்ன மாறியதுQ1 FY27 results show revenue growth but margin pressure from input costs and weather-related delays in the agrochemical business compared to the previous year.
ஏன் இது முக்கியம்The results demonstrate the company's diversified resilience; strength in Animal Nutrition and Oil Palm is currently offsetting temporary weaknesses in Crop Care and Dairy segments.
📅 குறுகிய காலம்The stock may see a neutral to slightly cautious reaction as the market weighs double-digit volume growth in core segments against the 8.5% decline in PBT.
📈 நீண்ட காலம்The structural shift toward high-margin value-added dairy products and the operational turnaround in Astec LifeSciences are positive indicators for long-term margin expansion.
👀 கவனிக்க வேண்டியவை
Monitor the recovery in Crop Care volumes as monsoon progresses and track the stabilization of milk procurement prices in the Dairy segment to see if margins recover.
13.8% Profit Dip in Q1; Godrej Agrovet Appoints Ex-HUL Finance Leader as New CFO
Godrej Agrovet reported a mixed Q1 FY27 with consolidated revenue growing 9.2% YoY to ₹2,855.22 Cr, while net profit declined 13.8% to ₹128.31 Cr due to higher operating expenses. The company announced a significant leadership transition, appointing Mr. Ravishankar A. (formerly VP Finance at HUL) as CFO effective October 1, 2026. This follows the early superannuation of current CFO Mr. S. Varadaraj on September 30, 2026. The new CFO brings experience managing a €1.5 billion portfolio, which may impact future capital allocation and strategic M&A.
உச்சம் நம்பிக்கை
என்ன மாறியதுGodrej Agrovet is transitioning its financial leadership to an external hire from HUL while reporting a year-on-year decline in quarterly profits despite revenue growth.
ஏன் இது முக்கியம்The appointment of a seasoned FMCG finance leader suggests a focus on operational excellence and strategic growth. However, the Q1 profit dip highlights ongoing margin pressures in the agri-business segments.
Q1 Consolidated Revenue: ₹2,855.22 கோடிQ1 Consolidated Net Profit: ₹128.31 கோடிQ1 வருவாய் vs TTM வருவாய்: ~27.9%YoY Profit Change: -13.8%CFO Effective Date: அக்டோபர் 1, 2026
📅 குறுகிய காலம்The stock may face slight pressure due to the YoY profit decline, though the high-quality management appointment could provide some support.
📈 நீண்ட காலம்The new CFO's experience in large-scale FMCG finance and M&A could be structurally positive for Godrej Agrovet's diversification into high-margin CDMO and value-added segments.
⚠ அபாய எச்சரிக்கைகள்
Margin compression due to rising operating expenses
Leadership transition risk
👀 கவனிக்க வேண்டியவை
Monitor the new CFO's strategy regarding margin improvement and capital allocation, especially given the current 8.4% OPM. Watch for the next quarterly results to see if revenue growth can be converted into profit recovery.
Godrej Agrovet Appoints Ex-HUL Executive as CFO; Q1 FY27 PAT at ₹128.3 Cr
Godrej Agrovet has appointed Mr. Ravishankar A, a former Vice President at Hindustan Unilever, as its new Chief Financial Officer effective October 1, 2026. This follows the early superannuation of the current CFO, Mr. S. Varadaraj, who will step down on September 30, 2026. For the quarter ended June 30, 2026, the company reported a 9.2% YoY increase in consolidated revenue to ₹2,855.22 crore, though consolidated PAT declined by 13.8% to ₹128.31 crore. The appointment brings in leadership with experience managing a €1.5 billion portfolio and significant M&A integration expertise.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is transitioning its financial leadership from a long-term incumbent to an external hire from Hindustan Unilever (HUL).
ஏன் இது முக்கியம்A CFO change in a ₹10,000+ Cr market cap company is a key governance event; hiring from a top-tier FMCG peer like HUL suggests a focus on improving operational excellence and financial controls.
📅 குறுகிய காலம்The stock may see minor pressure due to the 13.8% YoY decline in quarterly profits, though the high-profile CFO appointment may mitigate negative sentiment.
📈 நீண்ட காலம்The new CFO's expertise in M&A and strategic resource allocation could be pivotal as the company seeks to grow its high-margin CDMO and Vegetable Oil segments.
⚠ அபாய எச்சரிக்கைகள்
Leadership transition risk
Margin compression in the latest quarter
Volatility in raw material prices impacting profitability
👀 கவனிக்க வேண்டியவை
Investors should monitor the management transition in late September and watch for any shifts in capital allocation or M&A strategy, given the new CFO's background in portfolio transformation and acquisitions.
Godrej Agrovet Appoints Ravishankar A. as CFO; Q1 FY27 Revenue Grows 9.2% to Rs 2,855 Cr
Godrej Agrovet has announced a significant leadership transition with CFO S. Varadaraj opting for early superannuation effective September 30, 2026. He will be succeeded by Ravishankar A., a seasoned finance leader from Hindustan Unilever, effective October 1, 2026. For Q1 FY27, the company reported consolidated revenue of Rs 2,855.22 crore, up 9.2% YoY, though consolidated PAT declined 13.8% to Rs 128.31 crore compared to Rs 148.83 crore in Q1 FY26. The new CFO brings experience managing a €1.5 billion portfolio at HUL, which may support the company's strategic shift toward high-margin segments.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company is replacing its long-standing CFO with an external hire from Hindustan Unilever and has released its Q1 FY27 financial results.
ஏன் இது முக்கியம்A change in CFO at a large-cap agri-business is critical for financial discipline and strategic execution, especially as the company targets a 14% growth rate and higher-margin segments like CDMO and Palm Oil.
Q1 FY27 Revenue: Rs 2,855.22 கோடிQ1 FY27 PAT: Rs 128.31 கோடிYoY Revenue Growth: 9.2%Q1 வருவாய் vs TTM வருவாய்: 27.9%New CFO Experience: Over 20 years
📅 குறுகிய காலம்The stock may see neutral to slightly cautious sentiment due to the year-on-year decline in profitability despite revenue growth. The management transition is well-planned and unlikely to cause immediate disruption.
📈 நீண்ட காலம்The appointment of a seasoned leader from HUL could strengthen financial governance and strategic M&A execution, supporting the company's long-term diversification goals.
⚠ அபாய எச்சரிக்கைகள்
Margin compression (PAT down 13.8% YoY)
Transition risk during leadership change
Rising operating expenses
👀 கவனிக்க வேண்டியவை
Monitor the transition to the new CFO and his impact on capital allocation and margin improvement strategies. Investors should also track if the revenue growth translates into better operating margins in subsequent quarters, given the current YoY PAT decline.
Godrej Agrovet Q1 Revenue up 9.2% to ₹2,855 Cr; Net Profit Declines 13.8% YoY
Godrej Agrovet reported a 9.2% YoY increase in consolidated revenue to ₹2,855.22 Cr for Q1 FY27. However, consolidated net profit fell by 13.8% to ₹128.31 Cr compared to ₹148.83 Cr in the same quarter last year, primarily due to a 17.7% surge in raw material costs. The company also announced a major leadership change, appointing Mr. Ravishankar A. (formerly VP Finance at Hindustan Unilever) as the new CFO effective October 1, 2026, following the early superannuation of the current CFO.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its Q1 FY27 results showing top-line growth but bottom-line pressure, alongside a transition in the Chief Financial Officer role.
ஏன் இது முக்கியம்The profit decline highlights the impact of commodity price volatility on the agri-business. The appointment of a seasoned finance leader from HUL suggests a potential shift toward tighter financial controls and strategic portfolio management.
Consolidated Revenue (Q1 FY27): ₹2,855.22 கோடிConsolidated Net Profit (Q1 FY27): ₹128.31 கோடிYoY Revenue Growth: 9.2%YoY Profit Growth: -13.8%Cost of Materials vs Revenue: 72.0%
📅 குறுகிய காலம்The stock may face pressure due to the double-digit profit decline, though the high-profile CFO appointment from HUL may be viewed positively by institutional investors.
📈 நீண்ட காலம்The structural focus on high-margin segments like CDMO and Vegetable Oil remains key; the new CFO's experience in M&A and transformation could accelerate this shift.
⚠ அபாய எச்சரிக்கைகள்
Raw material price volatility
Margin compression (Cost of materials up 17.7% vs 9.2% revenue growth)
Management transition risk
👀 கவனிக்க வேண்டியவை
Investors should monitor the new CFO's impact on operational efficiencies and margin recovery, as raw material costs currently outpace revenue growth. Watch for the next quarterly update to see if the company can pass on these higher input costs to maintain margins.
Rs 11 Final Dividend: Godrej Agrovet Issues TDS Guidelines and Record Date Details
Godrej Agrovet has issued a formal communication regarding the tax deduction at source (TDS) for its recommended final dividend of Rs 11 per share (110% of face value) for FY 2025-26. The dividend is subject to shareholder approval at the 35th AGM scheduled for August 5, 2026. The record date for determining eligibility is July 29, 2026, with the book closure period starting July 30, 2026. Resident shareholders will be subject to a 10% TDS if their total dividend exceeds Rs 10,000, while non-residents face a 20% withholding tax unless treaty benefits are applied.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the administrative and tax procedures for the FY26 final dividend payout, including the setting of the record date and AGM schedule.
ஏன் இது முக்கியம்This is a routine but necessary procedural update for shareholders to receive their net dividend payout. It also highlights compliance with the newly enacted Income Tax Act, 2025, and SEBI's electronic-only payment mandate.
Final Dividend: Rs 11 per shareDividend Rate: 110%ரெக்கார்ட் தேதி: ஜூலை 29, 2026TDS Threshold (Resident): Rs 10,000டிவிடெண்ட் ஈல்ட்: 1.91%
📅 குறுகிய காலம்The stock is likely to trade ex-dividend around July 29, 2026, which typically results in a minor price adjustment corresponding to the dividend amount.
📈 நீண்ட காலம்Limited; this is a routine distribution of profits and does not alter the company's structural growth trajectory.
👀 கவனிக்க வேண்டியவை
Shareholders should ensure their PAN is linked with Aadhaar and bank account details are updated with their Depository Participant or RTA by the record date to ensure seamless electronic credit and avoid higher tax deductions.
Godrej Agrovet has inaugurated India's first integrated oil palm complex in Khammam, Telangana, involving a cumulative investment of ₹300 Crore. The facility integrates the entire value chain including a seed garden, nursery, R&D center, and a mill which has commenced operations at 30 tonnes per hour. This investment represents approximately 10.4% of the company's net worth (₹2,895 Cr). The complex is designed to support the company's target of tripling its plantation area in Telangana from 10,000 to 30,000 hectares by 2030.
உச்சம் நம்பிக்கை
என்ன மாறியதுGodrej Agrovet has moved from a fragmented supply chain to a fully integrated 'seed-to-refinery' model in Telangana with the inauguration of this new complex.
ஏன் இது முக்கியம்The integration improves operational efficiency and oil extraction ratios while securing the supply chain. As the vegetable oil segment is a high-growth area (41% growth previously), this capacity expansion is central to the company's diversification strategy away from animal feed.
Cumulative Investment: ₹300 CroreInvestment vs Net Worth: ~10.4%Initial Mill Capacity: 30 tonnes per hourTarget Plantation Area: 30,000 hectaresCurrent Plantation Area: 10,000 hectares
📅 குறுகிய காலம்The commencement of mill operations is likely to be viewed positively by the market as it signals immediate capacity addition in a key growth segment.
📈 நீண்ட காலம்This is a structural expansion that supports the company's goal of becoming a dominant player in India's edible oil security mission, potentially improving long-term margins through vertical integration.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution timeline for the upcoming refinery within the complex and the annual progress in plantation area expansion, which are critical for scaling the high-margin vegetable oil segment.
Godrej Agrovet has scheduled its 35th Annual General Meeting (AGM) for August 5, 2026, via video conferencing. The company has confirmed a final dividend of Rs 11 per equity share (110% of face value) for the financial year ended March 31, 2026. Shareholders must ensure their KYC and bank details are updated by the cut-off date of July 29, 2026, to receive the payout. The dividend is slated for payment on or before August 10, 2026, following a year where the company reported a TTM PAT of Rs 445 Cr.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has formalized the timeline for its 35th AGM and the distribution of the Rs 11 per share final dividend for FY 2025-26.
ஏன் இது முக்கியம்This is a routine but significant cash return to shareholders, representing a dividend yield of approximately 1.95% based on the current price of Rs 562.6. It confirms the company's commitment to distributing profits from its Rs 445 Cr TTM PAT.
Final Dividend: Rs 11 per shareடிவிடெண்ட் ஈல்ட்: ~1.95%Cut-off Date: ஜூலை 29, 2026Payment Date: ஆகஸ்ட் 10, 2026Face Value: Rs 10
📅 குறுகிய காலம்The stock may experience mild support or buying interest leading up to the July 29 cut-off date as investors seek to qualify for the Rs 11 dividend.
📈 நீண்ட காலம்Limited structural impact as this is a routine annual corporate action; however, consistent dividend payouts reflect stable cash flow management.
👀 கவனிக்க வேண்டியவை
Investors should verify that their PAN and bank account details are linked to their demat accounts before July 29, 2026, to ensure seamless dividend credit. Monitor the upcoming Annual Report for management's outlook on the high-margin CDMO and palm oil segments.
Godrej Agrovet Q4 FY26 Revenue Up 9% to ₹2,333 Cr; Annual Revenue Crosses ₹10,000 Cr
Godrej Agrovet reported a strong Q4 FY26 with consolidated revenue of ₹2,333 crores, a 9% YoY increase, and PBT growth of 16.8% to ₹87 crores. For the full year FY26, the company surpassed the ₹10,000 crore revenue milestone, finishing at ₹10,233 crores with a 17.2% PBT growth. Key drivers included a 15% volume growth in Animal Nutrition and EBITDA break-even for Astec LifeSciences. Management has provided a positive outlook for FY27, targeting double-digit revenue growth and mid-teen PBT growth.
முக்கிய அம்சங்கள்
Full-year FY26 revenue crossed the ₹10,000 crore milestone, reaching ₹10,233 crores (up 9% YoY).Animal Nutrition Q4 volumes grew 15% YoY, led by a 24% surge in cattle feed volumes.Astec LifeSciences achieved EBITDA break-even in FY26 with a strong turnaround in CDMO business.Oil Palm segment achieved record area expansion and all-time high oil extraction ratios.Management guides for double-digit revenue growth and mid-teens PBT growth in FY27.
👀 கவனிக்க வேண்டியவை
The stock remains a strong play on the Indian agri-economy given its diversified portfolio and improving margins. Investors should monitor the recovery in the Crop Care segment and the impact of global palm oil prices in FY27.
Godrej Agrovet FY26 Revenue Surpasses ₹10,000 Cr with All-Time High Profitability
Godrej Agrovet reported a robust FY26 with consolidated revenue growing 9.1% to ₹10,233 crore and PAT increasing 13.9% to ₹440 crore. The Oil Palm business was a standout performer with a 68% growth in segment results, while Animal Nutrition saw strong volume growth of 12%. Despite challenges in the Dairy and Crop Care segments due to high procurement costs and adverse weather, the company significantly optimized its working capital cycle from 45 to 25 days. Return on Capital Employed (ROCE) improved notably to 20% from 13% in the previous year.
முக்கிய அம்சங்கள்
Consolidated revenue crossed the ₹10,000 crore milestone, reaching ₹10,233 crore in FY26.Oil Palm business EBIT surged 67.9% YoY, driven by improved oil extraction ratios and supportive pricing.Animal Nutrition segment recorded 18% volume growth in cattle feed, contributing to a 19.3% rise in segment EBIT.Net Working Capital days significantly optimized from 45 days to 25 days, leading to an improved ROCE of 20%.Astec LifeSciences achieved an EBITDA break-even turnaround with a sharp reduction in losses compared to FY25.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant improvement in capital efficiency and the turnaround in the Astec LifeSciences subsidiary. The strong performance in core segments like Oil Palm and Animal Nutrition provides a cushion against cyclical pressures in the Dairy and Crop Care divisions.
Godrej Agrovet reported a robust FY26 performance with consolidated revenue crossing the ₹10,000 crore milestone, marking a 9.1% year-on-year growth. Profit Before Tax (excluding exceptional items) rose by 17.2% to ₹569 crore, driven by a stellar 68% EBIT growth in the Oil Palm business and strong volumes in Animal Nutrition. While the Dairy and Crop Care segments faced headwinds from high procurement costs and adverse weather, the company significantly improved capital efficiency. Net Working Capital days were reduced from 39 to 25, leading to an improved Return on Capital Employed (ROCE) of 20%.
முக்கிய அம்சங்கள்
Consolidated revenue grew 9.1% YoY to ₹10,233 crore, surpassing the ₹10,000 crore mark for the first time.Oil Palm segment results surged 67.9% YoY to ₹384 crore, supported by peak oil extraction ratios and better pricing.Animal Nutrition volumes increased by 11.6% YoY, with cattle feed volumes specifically growing by 18%.Net Working Capital (NWC) optimized significantly from 39 days to 25 days, boosting ROCE from 16% to 20%.Astec LifeSciences achieved EBITDA break-even in FY26, showing a sharp turnaround from a loss in the previous year.
👀 கவனிக்க வேண்டியவை
Investors should view the record revenue and significant improvement in capital efficiency as strong indicators of management's execution capability. The turnaround in Astec LifeSciences and growth in Oil Palm provide a solid margin cushion against volatility in the Dairy and Crop Care segments.
Godrej Agrovet FY26 PAT Up 10.4% to ₹445 Cr; ₹11 Dividend Declared
Godrej Agrovet reported a steady financial performance for FY26, with consolidated revenue from operations growing 9% to ₹10,232.68 crore. Full-year consolidated net profit increased by 10.4% to ₹445.18 crore, supported by a strong Q4 performance where profit jumped to ₹102.28 crore from ₹66.10 crore YoY. The Board has recommended a final dividend of ₹11 per share (110% of face value). The company also announced the allotment of 30,973 shares under its ESOP scheme.
முக்கிய அம்சங்கள்
Consolidated Revenue for FY26 rose to ₹10,232.68 crore, up from ₹9,382.77 crore in FY25.Full-year Consolidated Profit After Tax (PAT) grew 10.4% YoY to ₹445.18 crore.Recommended a final dividend of ₹11.00 per equity share (110%) for FY 2025-26.Q4 FY26 consolidated PAT stood at ₹102.28 crore, a significant jump from ₹66.10 crore in the same quarter last year.Paid-up equity share capital increased to ₹192.36 crore following the allotment of 30,973 ESOP shares.
👀 கவனிக்க வேண்டியவை
Investors may find the steady earnings growth and healthy dividend yield attractive; focus should remain on the company's ability to maintain margins amidst fluctuating agri-commodity prices.
Godrej Agrovet Shareholders Approve Re-appointment of Dr. Ashok Gulati with 99.99% Majority
Godrej Agrovet Limited has successfully passed a special resolution via postal ballot for the re-appointment of Dr. Ashok Gulati as a Non-Executive Independent Director. The resolution received overwhelming support with 99.9862% of votes cast in favour. A total of 14.51 crore votes were polled, representing approximately 75.45% of the company's total equity shares. Dr. Gulati's second term will run from May 7, 2026, through May 10, 2029, ensuring continuity in the company's independent board oversight.
முக்கிய அம்சங்கள்
Special resolution for re-appointment of Dr. Ashok Gulati passed with 99.9862% votes in favour.Total valid votes polled were 14,51,04,181, accounting for 75.45% of the total 19.23 crore outstanding shares.Promoter and Promoter Group cast 13.02 crore votes, all 100% in favour of the resolution.Public institutional holders showed strong support with 99.87% of their 1.47 crore votes in favour.The new term for the Independent Director is effective from May 7, 2026, to May 10, 2029.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the high level of shareholder consensus and the continuity of experienced independent leadership on the board. No immediate portfolio action is required as this is a positive governance-related update.
Godrej Agrovet Appoints Burjis Godrej as Chairman-Designate; Nadir Godrej to Retire in Aug 2026
Godrej Agrovet has announced a structured leadership succession plan where Mr. Nadir Godrej will retire as Chairman on August 13, 2026. Mr. Burjis Godrej, currently an Executive Director, has been appointed as Chairman-Designate effective April 13, 2026, and will formally assume the Chairperson role on August 14, 2026. Mr. Burjis Godrej brings significant operational experience, having served as MD of Astec LifeSciences (2025-2026) and COO of Crop Care (2023-2024). This long-term transition plan is designed to ensure stability and continuity in the company's strategic vision.
முக்கிய அம்சங்கள்
Mr. Nadir Godrej to retire as Chairman and Non-Executive Director effective August 13, 2026.Mr. Burjis Godrej appointed as Chairman-Designate effective April 13, 2026, and Chairman from August 14, 2026.Mr. Nadir Godrej will be appointed as Chairman Emeritus starting August 14, 2026.Burjis Godrej holds an MBA from Harvard and previously led Astec LifeSciences as MD from 2025 to 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive sign of transparent succession planning which reduces governance risk. No immediate portfolio changes are recommended as the transition period spans over a year.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
